Phenomenex Introduces Biozen dSEC-7, A New Way to Study AAVs with Unprecedented Speed and Efficiency

07.08.2025 - 18:06:49

Phenomenex California

particle technology and surface chemistry for characterizing AAVs result in consistent, reproducible results and facilitate a faster and more efficient mode of analysis compared to traditional methods. The newly designed particle allows for reduction in run times and sample consumption, ensuring that laboratories can achieve higher quality data for AAVs using these advancements in chromatographic methods.

Phenomenex reaffirms its commitment to leading chromatography solutions, empowering researchers and scientists with tools tailored to advance the frontiers of gene therapy and reshape the landscape of healthcare.

Additional Resources

Learn more about Phenomenex's biopharmaceutical solutionsWatch the webinar: Overcoming Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion ParticleDownload the Biozen dSEC-7 Solutions Guide

About Phenomenex
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in academic, pharmaceutical, biotech, environmental, clinical research, government, and industrial laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve human health and well-being. Phenomenex is an operating company within the Life Sciences group of Danaher Corporation.

For more information, please visit www.phenomenex.com and follow the company's blog at www.scienceunfiltered.com.

Let's connect: LinkedIn, Twitter, Facebook, Instagram and YouTube